Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Apr. 08, 2022 |
Nov. 19, 2020 |
Dec. 12, 2019 |
Sep. 30, 2022 |
Dec. 31, 2021 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|||
| Research and development expense | $ 3,706,828 | $ 4,621,255 | $ 12,811,462 | $ 10,343,451 | ||||||
| Deferred revenue | [1] | 1,408,000 | $ 33,000 | 1,408,000 | ||||||
| Revenue | 1,062,500 | 2,125,000 | $ 33,333 | |||||||
| BioNTech Agreement [Member] | ||||||||||
| Research and development expense | $ 2,750,000 | |||||||||
| Deferred revenue | $ 2,750,000 | |||||||||
| Revenue | 2,100,000 | |||||||||
| Revenue recognized | 688,000 | 1,400,000 | ||||||||
| License fee | 375,000 | 750,000 | ||||||||
| Accrued liabilities and other liabilities | 1,400,000 | 1,400,000 | ||||||||
| CFF Agreement [Member] | ||||||||||
| Grants receivable | 3,600,000 | 3,600,000 | ||||||||
| Additional milestone payment | 4,500,000 | 4,500,000 | ||||||||
| CFF Agreement [Member] | Accrued Liabilities [Member] | ||||||||||
| Other Liabilities | $ 194,000 | 899,000 | $ 194,000 | |||||||
| CFF Agreement [Member] | Cystic Fibrosis Foundation [Member] | ||||||||||
| Therapeutics development award | $ 4,200,000 | |||||||||
| Proceeds from award | $ 484,000 | |||||||||
| Additional milestone payment | $ 321,000 | |||||||||
| Genentech Feasibility Study Agreement [Member] | Genentech [Member] | ||||||||||
| Revenue | $ 33,000 | |||||||||
| Agreement description | Under the terms of the Genentech Agreement, Genentech paid the Company a total of $100 thousand for the development of three molecules, or $33 thousand per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement. The Company recorded the upfront consideration as deferred revenue, which is included in accrued expenses on the consolidated balance sheets. As of December 31, 2021, the Company completed its obligations related to the first and second of the three molecules. During the three and nine months ended September 30, 2022, the Company did not complete its obligations related to the remaining molecule but expects to do so by December 31, 2022. | |||||||||
| Aggregate revenue | $ 100,000 | |||||||||
| ||||||||||
| X | ||||||||||
- Definition Additional milestone payment. No definition available.
|
| X | ||||||||||
- Definition Agreement description. No definition available.
|
| X | ||||||||||
- Definition Commitment payment. No definition available.
|
| X | ||||||||||
- Definition License fee. No definition available.
|
| X | ||||||||||
- Definition Proceeds from award. No definition available.
|
| X | ||||||||||
- Definition Therapeutics development award. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|